Literature DB >> 19669654

Ranibizumab for retinal angiomatous proliferation.

Alexandros A Rouvas, Thanos D Papakostas, Ioannis D Ladas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19669654     DOI： 10.1007/s00417-009-1160-0

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  8 in total

1.  Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation.

Authors:  Sandra Joeres; Florian M A Heussen; Tobias Treziak; Silvia Bopp; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-17       Impact factor: 3.117

2.  Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

Authors:  Lazaros Konstantinidis; Evangelia Mameletzi; Irmela Mantel; Jean-Antoine Pournaras; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-04-29       Impact factor: 3.117

3.  Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation.

Authors:  Nicola G Ghazi; Robert M Knape; Tyler Q Kirk; James S Tiedeman; Brian P Conway
Journal:  Retina       Date:  2008-05       Impact factor: 4.256

4.  Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration.

Authors:  Timothy Y Y Lai; Wai-Man Chan; David T Liu; Dennis S Lam
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-09-28       Impact factor: 3.117

5.  Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation.

Authors:  K Bailey Freund; I-Van Ho; Irene A Barbazetto; Hideki Koizumi; Ketan Laud; Daniela Ferrara; Yoko Matsumoto; John A Sorenson; Lawrence Yannuzzi
Journal:  Retina       Date:  2008-02       Impact factor: 4.256

6.  Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation.

Authors:  Catherine B Meyerle; K Bailey Freund; Diana Iturralde; Richard F Spaide; John A Sorenson; Jason S Slakter; James M Klancnik; Yale L Fisher; Michael J Cooney; Lawrence A Yannuzzi
Journal:  Retina       Date:  2007 Apr-May       Impact factor: 4.256

7.  Pharmacokinetics of intravitreal ranibizumab (Lucentis).

Authors:  Sophie J Bakri; Melissa R Snyder; Joel M Reid; Jose S Pulido; Mohamed K Ezzat; Ravinder J Singh
Journal:  Ophthalmology       Date:  2007-12       Impact factor: 12.079

8.  Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study.

Authors:  Alexandros A Rouvas; Thanos D Papakostas; Demetrios Vavvas; Ioannis Vergados; Marilita M Moschos; Athanasios Kotsolis; Ioannis D Ladas
Journal:  Retina       Date:  2009-04       Impact factor: 4.256
  8 in total
  1 in total

1.  [Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].

Authors:  A Lommatzsch; B Heimes; M Gutfleisch; G Spital; M Dietzel; D Pauleikhoff
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.